- Home
- Publications
- Publication Search
- Publication Details
Title
Lenalidomide in the treatment of chronic lymphocytic leukemia
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 5, Pages 633-650
Publisher
Informa UK Limited
Online
2017-04-08
DOI
10.1080/13543784.2017.1313230
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
- (2017) A Chanan-Khan et al. LEUKEMIA
- A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL
- (2016) Ian W. Flinn et al. AMERICAN JOURNAL OF HEMATOLOGY
- The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor
- (2016) Michael Y. Choi et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
- (2016) A. Albertsson-Lindblad et al. BLOOD
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
- (2016) K. M. Kortum et al. BLOOD
- Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study
- (2016) Julie E. Chang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
- (2016) C. Vitale et al. CLINICAL CANCER RESEARCH
- Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
- (2016) Nianhang Chen et al. CLINICAL PHARMACOKINETICS
- Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia
- (2016) Christian Maurer et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
- (2016) LANCET ONCOLOGY
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
- (2016) Susan O'Brien et al. LANCET ONCOLOGY
- IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)
- (2016) J Krönke et al. LEUKEMIA
- Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*
- (2016) Clemens M. Wendtner et al. LEUKEMIA & LYMPHOMA
- Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial
- (2016) Francesca R. Mauro et al. LEUKEMIA & LYMPHOMA
- Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
- (2016) Julio C. Chavez et al. LEUKEMIA RESEARCH
- Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity
- (2016) Ruth Eichner et al. NATURE MEDICINE
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- A review of the venous thrombotic issues associated with multiple myeloma
- (2016) Despina Fotiou et al. Expert Review of Hematology
- Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
- (2016) A Bühler et al. Blood Cancer Journal
- Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells
- (2016) R. L. Browning et al. Cancer Immunology Research
- Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
- (2015) Michael Hallek AMERICAN JOURNAL OF HEMATOLOGY
- Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia
- (2015) Anthony R. Mato et al. AMERICAN JOURNAL OF HEMATOLOGY
- Targeted therapies in CLL: mechanisms of resistance and strategies for management
- (2015) J. A. Woyach et al. BLOOD
- Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
- (2015) C. Y. Cheah et al. BLOOD
- Perturbation of the normal immune system in patients with CLL
- (2015) F. Forconi et al. BLOOD
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
- (2015) P. A. Thompson et al. BLOOD
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- (2015) K. Fischer et al. BLOOD
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
- (2015) P. Jain et al. BLOOD
- Practical Management of Lenalidomide-Related Rash
- (2015) Sara M. Tinsley et al. Clinical Lymphoma Myeloma & Leukemia
- The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression
- (2015) Petra Langerbeins et al. Future Oncology
- Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
- (2015) John G. Gribben et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
- (2015) Mohammed Z H Farooqui et al. LANCET ONCOLOGY
- Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
- (2015) V Goede et al. LEUKEMIA
- Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells
- (2015) Giovanni D’Arena et al. LEUKEMIA & LYMPHOMA
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
- (2015) Pavel Otáhal et al. OncoImmunology
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
- (2015) Kami J. Maddocks et al. JAMA Oncology
- Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels
- (2015) Tait D. Shanafelt et al. Journal of Oncology Practice
- Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
- (2014) C. S. Tam et al. BLOOD
- Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia
- (2014) L. Jia et al. BLOOD
- Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53
- (2014) J.-F. Fecteau et al. BLOOD
- Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia
- (2014) Christine I. Chen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia
- (2014) S. Fiorcari et al. HAEMATOLOGICA
- Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia
- (2014) F. J. Gassner et al. HAEMATOLOGICA
- Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium
- (2014) Danelle F. James et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
- (2014) Luciano J. Costa et al. LEUKEMIA & LYMPHOMA
- Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma
- (2014) Chaitra Ujjani et al. LEUKEMIA & LYMPHOMA
- A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia
- (2014) Kami Maddocks et al. LEUKEMIA RESEARCH
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease
- (2014) Leticia Huergo-Zapico et al. PLoS One
- Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
- (2014) Andrea Acebes-Huerta et al. Biomed Research International
- Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
- (2013) Aristoteles Giagounidis et al. ANNALS OF HEMATOLOGY
- Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment
- (2013) A. Schulz et al. BLOOD
- Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
- (2013) P. Strati et al. BLOOD
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)
- (2013) T. D. Shanafelt et al. BLOOD
- Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide
- (2013) A. G. Ramsay et al. BLOOD
- High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
- (2013) Daniel Heintel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
- (2013) Anita K. Gandhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia
- (2013) Rossana Maffei et al. EXPERIMENTAL HEMATOLOGY
- Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia
- (2013) John C. Riches et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
- (2013) A Thakurta et al. LEUKEMIA
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel, Non-canonical Splice Variant of the Ikaros Gene Is Aberrantly Expressed in B-cell Lymphoproliferative Disorders
- (2013) Daria Capece et al. PLoS One
- Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity
- (2013) Iwona Hus et al. PLoS One
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
- (2012) A. Broyl et al. BLOOD
- RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans
- (2012) A. Troeger et al. BLOOD
- Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
- (2012) A. G. Ramsay et al. BLOOD
- Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
- (2012) Ling-Hua Zhang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity
- (2012) N. Chen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2012) Xavier C. Badoux et al. JOURNAL OF CLINICAL ONCOLOGY
- Stromal Endothelial Cells Establish a Bidirectional Crosstalk with Chronic Lymphocytic Leukemia Cells through the TNF-Related Factors BAFF, APRIL, and CD40L
- (2012) M. Cols et al. JOURNAL OF IMMUNOLOGY
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia
- (2011) Georg Aue et al. AMERICAN JOURNAL OF HEMATOLOGY
- The role of phosphatidylinositol 3-kinase- in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia
- (2011) S. E. M. Herman et al. BLOOD
- Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
- (2011) X. C. Badoux et al. BLOOD
- Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
- (2011) X. C. Badoux et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Nurse-like cells show deregulated expression of genes involved in immunocompetence
- (2011) Nupur Bhattacharya et al. BRITISH JOURNAL OF HAEMATOLOGY
- Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner
- (2011) Aisha Masood et al. BRITISH JOURNAL OF HAEMATOLOGY
- Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
- (2011) Asher A. Chanan-Khan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia
- (2011) Bang-Ning Lee et al. CANCER
- Physical contact with endothelial cells through 1- and 2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells
- (2011) R. Maffei et al. HAEMATOLOGICA
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
- (2011) Clemens-Martin Wendtner et al. LEUKEMIA & LYMPHOMA
- Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia
- (2010) R. Maffei et al. BLOOD
- Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications
- (2010) K. Billot et al. BLOOD
- Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia
- (2010) Lukas Weiss et al. CANCER
- Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response
- (2010) Asher Chanan-Khan et al. CANCER
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
- (2010) Christine I. Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Distribution of Lenalidomide Into Semen of Healthy Men After Multiple Oral Doses
- (2010) Nianhang Chen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL
- (2010) J R Brown et al. LEUKEMIA
- Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
- (2010) Taimur Sher et al. LEUKEMIA & LYMPHOMA
- Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease
- (2010) Giovanni D’Arena et al. LEUKEMIA RESEARCH
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
- (2009) R. Lapalombella et al. BLOOD
- Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression
- (2009) Wei Ding et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells
- (2009) Irina Idler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
- (2009) G. Aue et al. HAEMATOLOGICA
- Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia
- (2009) K Giannopoulos et al. LEUKEMIA
- Enhanced formation and survival of CD4+CD25hiFoxp3+T-cells in chronic lymphocytic leukemia
- (2009) Margot Jak et al. LEUKEMIA & LYMPHOMA
- Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
- (2008) I. Iacobucci et al. BLOOD
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
- (2008) R. Lapalombella et al. BLOOD
- Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
- (2008) A. Ferrajoli et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction
- (2008) Gondi Kumar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
- Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia
- (2008) Leslie A. Andritsos et al. JOURNAL OF CLINICAL ONCOLOGY
- BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
- (2008) Charles G. Mullighan et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started